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Abstract: Anemia is a common finding in congestive heart failure (CHF) and is associated 
with an increased mortality and morbidity. Several conditions can cause depression of erythroid 
progenitor cells: reduction of iron absorption and reuptake, decreased bone marrow activity, 
reduced endogenous erythropoietin production, and chronic inflammatory state. Anemia’s 
etiology in CHF is complex and partially understood; it involves several systems including 
impaired hemodynamic condition, reduced kidney and bone perfusion, increased inflammatory 
activity, and neurohormonal overdrive. The use of erythropoiesis stimulating agents (ESAs) 
such as erythropoietin and its derivatives is recently debated; the last interventional trial seems 
to demonstrate a neutral or negative effect in the active arm with darbepoetin treatment. The 
current data is opposite to many single blind studies and previous meta-analysis showing an 
improvement in quality of life, New York Heart Association class, and exercise tolerance using 
ESA therapy. These contrasting data raise several concerns regarding the target of hemoglobin 
levels needing intervention, the exact anemia classification and categorization, and the stan-
dardization of hematocrit cutoffs. Some cardiac and systemic conditions (ie, hypertension, atrial 
fibrillation, prothrombotic status) may predispose to adverse events, and ESA administration 
should be avoided. To prevent the negative effects, high-dosage and chronic administration 
should be avoided. Clarification of these items could probably identify patients that may benefit 
from additional iron or ESA treatment. In this review, we discuss the interventional trials made 
in anemic heart failure patients, the underlying mechanism of anemia in CHF, and the potential 
role of ESA in this setting.
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Introduction
In a recent US report, the first year mortality after a diagnosis of congestive heart fail-
ure (CHF) is about 20%, and only 25% survive 5 years after the first diagnosis.1 The 
estimated direct and indirect cost of CHF in the US is consistently growing. Anemia 
is a common condition associated with CHF, as with other unfavorable clinical con-
ditions such as diabetes, malnutrition, chronic kidney disease (CKD), and advanced 
age. Anemia is related to a poor outcome, and it is an independent risk factor for more 
severe CHF, hospitalization, and death.2–10 Therefore, it is correlated with reduced 
quality of life and exercise tolerance, increased New York Heart Association (NYHA) 
class, and use of high diuretic dosage.
Anemia, regardless of its definition, is common in CHF, being found in 4% to 50% of 
cases, and its prevalence in CHF may be rising.9,10 The wide range of prevalence depends 
on several factors: the definition of anemia and its cutoff varies across global societies 
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(World Health Organization versus National Kidney Founda-
tion); different inclusion criteria in multicenter  studies; and 
poor information about etiology and pathogenesis.10,11 Few 
studies detailed the specific causes of anemia in the heart 
failure (HF) setting; most gave different results regarding 
its etiology and described anemia as a chronic inflamma-
tory condition without explaining the precise determinant. 
Because of the current confusion in the classification and 
definition of anemia, interventional trials reported different 
results, thus demonstrating a need to understand whether 
ESA treatment is dangerous, in which patients should it be 
avoided, and which treatment is the best therapeutic option 
for anemic CHF patients.
Underlying causes of anemia  
in CHF
The mechanisms of anemia development in patients with 
CHF have not been entirely elucidated, and several factors 
with different impact and timing may be simultaneously 
involved. Although anemia is common in patients with CHF, 
only few studies have investigated the topic of the causes of 
anemia in CHF. The principal determinants of anemia are 
to due to hemodynamic impairment with consequent water 
and salt retention, kidney dysfunction due to reduced renal 
flow, tubuloglomerular damage. The resultant reduction in 
erythropoietin (EPO) production, deranged bone metabolism, 
reduced nutritional absorption due to gastrointestinal edema, 
and systemic proinflammatory status. It is possible to distin-
guish two main pathophysiological mechanisms in acute and 
chronic HF. In acute status the prevalent mechanism could be 
recognized in the increase of intra- and extracellular plasma 
content due to hydrosaline retention and fluid overload (false 
anemia); whereas, in the chronic state, CKD and renal blood 
flow redistribution are the most prevalent mechanisms that 
leads to relative reduction in erythropoietin production.3
Iron deficiency
The prevalence of iron deficiency in patients with HF is vari-
able, from 20% to 50%.12 In a recent study,13 43% of patients 
had either low serum iron (,8 µmol/L) or ferritin (,30 
µg/L), but microcytic anemia was observed in only 6% of 
patients. In contrast, Nanas et al14 found depleted iron stores 
in the bone marrow of 73% of patients despite normal serum 
iron, ferritin, and EPO. In normal conditions, iron is absorbed 
by the enterocytes of the gastrointestinal mucosa from diet 
intake, and it is also recycled from red blood cells and moved 
from storage sites in the liver. Nearly all of the iron available 
for erythropoiesis originates from the recycling of senescent 
red blood cells carried out by macrophages and reticuloen-
dothelial cells. Thereafter, iron is transported from the inside 
of the cells to the outside by the carrier protein ferroportin-1 
and carried on by the iron-binding blood plasma glycoprotein 
transferrin.15–17 During HF stages, inflammatory cytokines, 
particularly hepcidin, cause a reduction in iron absorption 
by blocking ferroportin-1 in the basolateral membrane of 
enterocytes, with consequent inhibition of iron absorption 
in the bowel. In addition to this effect, hepcidin blocks fer-
roportin-1 in the macrophages and reticuloendothelial cells, 
preventing iron from being exported from the inside of the 
cells and consequently leads to a reduction in transferrin 
uptake.17,18 Intravenous (IV) iron therapy has been shown 
to increase serum hemoglobin (Hb) levels (from 11.2±0.7 
to 12.6±1.2 g/dL, P=0.0007) as well as improve exercise 
tolerance, quality of life, and functional class.19 Vitamin 
B12 and folate deficiency do not have a significant role in 
the pathogenesis of anemia in patients with HF.
Chronic kidney disease
CKD is common in CHF, and it is associated with reduced 
production of EPO in the kidney. The renal damage is due 
mainly to hemodynamic and parenchymal derangements. 
Hemodynamic alteration consists of reduced renal blood flow 
and intrarenal blood flow redistribution that causes hypoxic 
renal damage; parenchymal injury is due to tubulointerstitial 
fibrosis, tubular loss, and glomerulosclerosis.
The adverse liaison linking heart failure with anemic 
status is the impaired endogenous EPO synthesis and tissue 
resistance.20–22 EPO is a glycoprotein hormone produced 
primarily in the kidney by specialized peritubular fibroblasts. 
It regulates erythroid cell proliferation in the bone marrow 
in response to tissue hypoxia. The primary stimulus for EPO 
production is reduced oxygen tension that induces the tran-
scription of the EPO gene. This in turn stimulates erythroid 
cell proliferation and differentiation. Oxygen delivery into 
the kidney is determined by renal blood flow, hematocrit, and 
the PO
2
 of the Hb oxygen-dissociation curve. Conversely, 
oxygen consumption is determined by proximal tubular 
sodium reabsorption and the glomerular filtration rate. Both 
hemodynamic and parenchymal distortion may contribute to 
a reduction in EPO production although recruited endogenous 
levels do not explain the degree of anemia in HF patients.23
Inflammatory status
Inflammatory cytokines elaborated in CHF, such as tumor 
necrosis factor alpha and interleukin-6, can cause anemia 
by reducing EPO production in the kidney and its  activity 
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in the bone marrow and by eliciting EPO resistance at the 
peripheral tissue level.24 All these occurrences are mediated 
by a specific peptide produced by the liver acting as in the 
erythroid metabolism as in the iron absorption and reuptake: 
hepcidin. It proceeds by blunting EPO and erythroid progeni-
tor cell production at bone level; therefore, it raises tissue 
EPO resistance by reducing EPO gene expression, perturbing 
EPO signal transduction, and downregulation of EPO recep-
tors.25 As previously reported, hepcidine inhibits the protein 
ferroportin-1, leading to a reduction in gastrointestinal iron 
absorption as in iron release from its storage (macrophages 
and reticuloendothelial cells).17 This results in low serum 
iron and decreased delivery of iron to the bone marrow, and 
thus iron deficiency anemia (the so called functional iron 
deficiency anemia). This inflammatory-induced anemia is 
probably the main cause of anemia in CHF and the anemia 
of chronic disease.17,24–26
Use of angiotensin converting enzyme 
inhibitors and beta blockers
Since angiotensin is a stimulator of EPO production and 
erythropoiesis, angiotensin converting enzyme inhibitors 
and beta blockers can cause reduced production of EPO and 
reduced activity of EPO in the bone marrow.  Angiotensin 
converting enzyme inhibitors also increase the levels 
of erythropoietic inhibitors in the blood, further inhibiting 
 erythropoiesis. Peritubular cells producing endogenous EPO 
receive sympathetic innervations; therefore, a specific sub-
unit beta 2 receptor shares similar chemical heterodimeric 
characteristics with the EPO receptors. These two conditions 
together could explain the reduced EPO production and resis-
tance in patients undergoing beta blocker therapy.27,28
Hemodilution
It has been suggested that the anemia in CHF is secondary, 
in many cases, to hemodilution.12,29,30 This has recently been 
further investigated.31 It was found that a red cell deficit was 
present in 88% of CHF patients with anemia and diastolic 
CHF and in 59% of those with systolic CHF. All systolic 
CHF patients and 71% of the diastolic CHF patients also 
had expanded plasma volume. This study suggests that 
there is a true red cell deficit in the majority of anemic CHF 
patients.
Gastrointestinal absorption and bleeding
Gastrointestinal absorption and bleeding due to aspirin, 
warfarin-like agents, malignant tumors, polyps, esophagitis, 
or reduced iron absorption resulting from atrophic gastritis 
are common causes of anemia in HF. Therefore, during 
refractory HF stages characterized by fluid overload and 
redistribution, with an increase in abdominal fluid compo-
nent and pressure, there is abnormal bowel absorption due to 
mucosae edema, venous congestion, and reduced lymphatic 
drainage (Figure 1).32
Correction of anemia in CHF
The strong association of anemia with poor clinical status 
and high mortality rates led to increasing exploration of the 
treatment of anemia as a therapeutic target in HF patients. 
Only three options are currently available to increase Hb: 
blood transfusion, iron infusion, and erythropoiesis stimulat-
ing agent (ESA) administration. Although blood transfusion 
can be used as an acute therapy, it is associated with many 
risks and provides only temporary benefits.33 According to the 
American guidelines,33 blood transfusion is recommended for 
Hb levels in the range from 6–8 g/dL, thus the clinical utility 
of hemotransfusion for higher Hb levels is not well defined. 
However, blood transfusion is associated with several adverse 
effects such as suppression of the immune system, increased 
infection risk, iron overload, and sensitization to human 
leukocyte antigens.34 For these reasons, transfusion should 
be avoided for long-term treatment and may be considered 
only in the acute phase in severe anemia status. 
iron supplementation therapy
Given the high prevalence of iron deficiency in patients 
with HF and the close association between iron deficiency 
and HF prognosis, the treatment of iron deficiency has 
gained increasing attention. Iron is essential not only for 
erythropoiesis but also for several enzyme-linked bioener-
getic processes in skeletal muscles and in the Krebs cycle. 
However, iron therapy at high doses has severe side effects, 
such as a greater oxidative stress on the endothelial tissue 
and atherosclerosis progression. Moreover, iron supplemen-
tation may have potential side effects such as anaphylaxis, 
increased risk of developing bacteremia, and shock. Sev-
eral observational and uncontrolled trials35–37 have shown 
a promising association between IV iron replacement and 
improved symptoms in HF patients. To date, there are only 
a few randomized, controlled trials evaluating the efficacy of 
iron supplementation alone, without ESA, on HF outcomes. 
The number of randomized, controlled trials evaluating the 
role of iron supplementation is exiguous, and none of them 
assessed hard clinical end points of HF hospitalization or 
death as primary end points. Three recent studies of IV iron 
administration in anemic CHF patients, two uncontrolled 
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studies and a double-blind placebo-controlled study, have 
shown improved Hb, left ventricular ejection fraction 
(LVEF), NYHA class, quality of life, left ventricular ejection 
fraction (LVEF), NYHA class, quality of life,  and exercise 
capacity reducing BNP, C-reactive protein (CRP) and hos-
pitalization. Another small, randomized controlled trial, the 
Ferric Iron Sucrose in Heart Failure Trial,13 evaluated the 
effect of 16 weeks of IV iron sucrose in patients with iron 
deficiency (ferritin G 100 ng/mL or ferritin 100–300 ng/mL 
with transferrin saturation 20%) and found improvement in 
functional capacity and symptoms. In the largest controlled 
study, the Ferric Carboxymaltose Assessment In Patients 
With Iron Deficiency And Chronic Heart Failure With And 
Without Anemia Trial,38 which recruited 459 patients with 
HF and iron deficiency (defined as ferritin G 100 ng/mL, or 
between 100–299 ng/mL and transferrin saturation ,20%), 
the effect of IV ferric carboxymaltose or saline was evalu-
ated. The active arm demonstrated a significant improvement 
in symptoms and NYHA class, although mortality rate did 
not differ between treatment and placebo groups. Oral iron 
is inexpensive and effective, but compliance is often limited 
by significant gastrointestinal side effects; up to 70% of 
patients were not taking oral iron as prescribed in clinical 
practice. In addition, various malabsorptive states such as 
decreased bowel drainage, CKD, and fluid redistribution 
may decrease a patient’s ability to absorb oral iron. One 
such trial, Iron Supplementation in Heart Failure Patients 
With Anemia, is now in progress, and it compares IV iron, 
oral iron supplementation, and placebo.39
eSAs in heart failure
Several small studies in HF have tested the effects of increas-
ing Hb with ESAs. Such treatments have been reported in 
patients with CHF in whom the anemia has been treated 
with ESAs such as EPO or its derivative, the longer acting 
darbepoetin, alone or with the addition of either oral or IV 
iron. In the first study, Silverberg et al40 described the effect 
of epoetin alfa and IV iron in 26 patients with anemia and 
HF. An increase in Hb was associated with an improvement in 
NYHA functional class and LVEF and a decrease in diuretic 
dose and hospitalization. Similar results were reported 1 year 
later by the same authors in a randomized, open label trial in 
which EPO significantly decreased hospitalization and wors-
ened NYHA class. Mancini et al41 conducted a patient-blind, 
randomized study in 23 HF patients with anemia. Patients 
were randomized to epoetin alfa plus oral iron and folate or 
placebo. After 3 months, EPO therapy was associated with sig-
nificant increase in Hb values from 11.0±0.5 to 14.3±1.0 g/dL, 
with a concomitant increase in 6-minute walk distance and 
peak oxygen uptake (11.0±1.8 to 12.7±2.8 mL/minute per 
kilogram; P,0.05). The increases in Hb levels were linearly 
associated with the increase in peak oxygen uptake.
More recently, our group reported the effects of epoetin 
beta and oral iron on LV structure and function, pulmonary 
Heart failure
Renal
dysfunction
InflammationActivation of RAAS, SNS, and AVP
Renal perfusion
Renal blood flow
EPO production
Cytokines
Iron  availability
Erythropoiesis
Half life red cells
Fluid overload
Erythropoiesis
ErythropoiesisHemodilution
Anemia
PO2 peritubular
EPO production
Figure 1 Relationship among anemia renal dysfunction and heart failure: possible mechanisms of reduced and blunted erythropoietin production.
Abbreviations: AvP, arginine vasopressin; ePO, erythropoietin; PO2, partial pressure of oxygen; RAAS, renin-angiotensin-aldosterone system; SNS, sympathetic nervous 
system. 
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artery pressure, and BNP in 51 anemic HF patients with 
CKD.42 After 1 year, Hb increased, LV dimensions, volume, 
and mass decreased, and LVEF increased in the epoetin group, 
with no change in the control group. The pulmonary artery 
pressure and BNP blood levels also decreased as well as the 
need for hospitalization in patients treated with EPO.
The randomized, placebo-controlled trial carried out 
by Ponikowski et al43 in which 41 patients with HF anemia 
were treated with darbepoetin-alpha once every 2 weeks 
for 26 weeks showed an increase in Hb values with con-
comitant improvement in quality of life as evaluated by 
Patient’s Global Assessment; however, no differences were 
revealed regarding peak VO
2
, exercise duration, BNP, and 
renal function between treatment groups. Despite the ben-
eficial effects shown in these trials, the sample sizes of the 
studies were also relatively small, preventing far-reaching 
applications. Moreover, none of the smaller randomized, 
controlled trials evaluated hard clinical outcomes such as 
all-cause mortality or HF hospitalization as primary end 
points, and they were limited by small sample size, limited 
duration, and lacked double-blind study design. On the other 
hand, in another single randomized, double-blind, placebo-
controlled trial44 involving 165 HF patients with anemia, 
LVEF ,40%, and Hb 9.0–12.5 g/dL, subcutaneous treat-
ment with darbepoetin alpha every 2 weeks for 26 weeks at 
a starting weight-adjusted dose of 0.75 µg/kg (n=56) or a 
fixed dose of 50 µg (n=54) (placebo group n=55) gradually 
achieved and maintained a target Hb of 14.0±1.0 g/dL. The 
rate of Hb rise was equivalent between darbepoetin alpha 
weight-based and fixed dose groups. There were nonsignifi-
cant improvements in the combined darbepoetin alfa group 
versus placebo for 6-minute walk distance (P=0.074) and 
Patient’s Global Assessment score (P=0.057). There was a 
significant improvement in the Kansas City Cardiomyopathy 
Questionnaire total symptom score without change in NYHA 
class, LVEF, and the Minnesota Living With Heart Failure 
Questionnaire score. However, in the two larger multicenter 
double-blind, placebo-controlled studies using darbepoetin 
(Study of Anemia in Heart Failure Trial [STAMINA-HF] 
and Reduction of Events With Darbepoetin Alfa in Heart 
Failure [RED-HF] Trial),45,46 no significant improvement 
was found in either NYHA class, hospitalization, or death. 
In the STAMINA-HF Trial, 319 HF patients with LV systolic 
dysfunction (LVEF ,40%) and Hb .9–12.5 g/dL were ran-
domized to placebo or darbepoetin alpha every 2 weeks for 1 
year (target Hb, 14.0±1.0 g/dL). The primary end point was a 
change from baseline to week 27 in treadmill exercise time. 
Secondary end points were a change from baseline to week 
27 in NYHA class and quality of life. An additional, prespeci-
fied efficacy analysis included the time of death by any cause 
or first HF-related hospitalization by 1 year. At baseline, 
the median (interquartile range) Hb was 11.4 (10.9–12.0) 
g/dL. At week 27, darbepoetin alpha treatment increased 
median (interquartile range) Hb by 1.8 (1.1–2.5) g/dL. 
Despite this trend, darbepoetin treatment did not signifi-
cantly improve exercise duration, NYHA class, or quality 
of life score compared with placebo. A difference, although 
nonsignificant, toward a lower risk of all-cause mortality 
and first HF hospitalization was observed in the darbepoetin 
arm versus the placebo (hazard ratio 0.68; 95% confidence 
interval 0.43–1.08; P=0.10). The incidence of other adverse 
events including development of hypertension and myocar-
dial infarction was similar in the two groups.45
In the largest multicenter randomized, controlled 
trial (RED-HF) enrolling 2,278 patients with systolic HF 
(LVEF #40%, NYHA class $2) and anemia (Hb 9–12 g/dL), 
the darbepoetin alfa dose was adjusted to achieve a goal 
Hb of $13 g/dL. After a median follow up of 28 months, 
Hb increased from 11.2–13.0 g/dL in the active arm, and it 
remained unchanged in the placebo group. There was no sig-
nificant difference between the darbepoetin alfa and placebo 
groups for the primary composite outcome of death from 
any cause or first HF hospitalization (50.7% versus 49.5%, 
respectively, with a hazard ratio of 1.01; 95% confidence 
interval 0.90–1.13; P=0.87). Therefore, no benefit was found 
regarding all other secondary outcomes including all-cause 
mortality, cardiovascular death, HF-related hospitalization, 
and coronary events. Despite these neutral effects of darbe-
poietin, an increased rate of thromboembolic events was seen 
in the treated patients compared with placebo (13.5% versus 
10.0%; P=0.01). In line with the above data, an increased risk 
of stroke in the darbepoetin alfa group has been revealed 
(5.4% versus 3.9%) (Table 1).46
Two previous meta-analysis, not including RED-HF data, 
demonstrated that patients treated with ESAs had a significant 
increase in quality of life, exercise tolerance, and NYHA class 
associated with lower risk of CHF  hospitalization. Signifi-
cant differences in mortality and risk of adverse events were 
found between the  ESA and placebo groups, with a reduc-
tion of mortality risk and adverse events in the ESA-treated 
patients.47,48 A further meta-analysis including RED-HF 
data is mandatory to better define beneficial/adverse effects 
ratio by ESA administration. The differences among all of 
these reports may be partially explained by use of different 
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protocols, various ESA administration and dosage, and dif-
ferent degrees of anemia.
Potential risks of ESA therapy
Correcting anemia in HF is a tradeoff between the  favorable 
effects of improving oxygen delivery and the unfavor-
able effects of increasing viscosity, blood pressure, and 
thrombocytosis. In this sense, many studies have shown 
that ESA therapy is associated with an increased prevalence 
and severity of cardiovascular events, including myocardial 
infarction, stroke, and venous thromboembolism.49–53
EPO can potentially increase the platelet count.51,54–56 
This action can be related both to an indirect effect of 
EPO leading to iron deficiency and a direct effect of the 
hormone49,51 that enhances the action of thrombopoietin, 
and thus increases platelet activation. Correction of iron 
deficiency with IV iron in EPO-treated dialysis patients 
reduces the platelet count significantly,57 thus thrombo-
cytosis may be one of the missing links in causing the 
increased incidence of cardiovascular events associated 
with EPO in CKD and CHF. Iron deficiency also increases 
oxidative stress.58 These effects may be due to an increase 
in platelet aggregation by effects on proteins C and S as 
well as endothelial activation.
A recent meta-analysis has shown that EPO therapy is 
associated with a trend of increased risk of venous thrombosis 
and cerebrovascular events in four studies in patients with 
Hb target levels of 12.5–15.0 g/dL.59 However, no difference 
between ESA and control groups was shown for patients with 
lower Hb levels.59
Biological effects of ESA beyond 
erythropoiesis
Several studies have confirmed that ESAs decrease experi-
mental infarct size, reduce hypoxic injury, prevent myocyte 
apoptosis, and mobilize endothelial progenitor cells (EPCs) 
independently from Hb levels. These beneficial effects of 
ESAs appear unrelated to their effect on Hb increase, and they 
occur even when administered at low dosage. The usefulness 
of ESAs in CHF has been shown in animal studies, where 
their use in CHF after a myocardial infarction or after cardiac 
damage from other causes, with or without improving the Hb, 
improved endothelial dysfunction, increased neovasculariza-
tion of heart muscle, reduced apoptosis of the cardiomyocytes, 
oxidative stress, inflammation, fibrosis, hypoxic damage, and 
prevented functional impairment of the heart.60–62 At least 
part of these effects is related to the increase in the number 
and activity of endothelial and vascular growth factors due to 
raised activity of EPCs from the bone marrow.60–62 In CHF,63 
as in CKD,64 there is a relative reduction in the number of 
capillaries to the number of myocytes; therefore, neovascu-
larization and other processes activated by ESA may improve 
the microvessel number into myocardial tissue. In an animal 
study, Westenbrink et al12 observed that neovascularization 
induced by EPO in HF following myocardial infarction was 
induced by several mechanisms including EPC recruitment 
from the bone marrow and increased myocardial expression 
of vascular endothelial growth factor (Figure 2). That study 
showed, in particular, that EPO’s effects appear 3 weeks after 
myocardial infarction and increased the mobilization, myo-
cardial homing, and vascular incorporation of EPCs.
Inhibition of myocyte apoptosis Stimulation of neovascularization
ErythropoietinStimulation of erythropoiesis Increased hematocrit levels
Increased expression of beta
chain myosin
reduced infarct size
Increased expression
of vascular and endothelial
growth factors
Figure 2 eSA effects beyond erythropietic capacity: potential endothelial and intracellular signaling effects.
Abbreviation: eSA, erythropoiesis stimulating agent.
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Open questions and future 
directions
In HF patients with moderate-to-severe anemia (Hb ,11 g/dL), 
current guidelines of the US Food and Drug Administration 
and of the National Kidney Foundation65,66 state that dosing 
should be individualized to achieve and maintain Hb levels 
within the range of 10–12 g/dL.  Currently there are no clinical 
data supporting the use of ESAs to improve the outcome in 
HF patients. The 2012 guidelines of the European Society of 
Cardiology67 underlined that anemia is a frequently associated 
condition in HF patients; however, they do not indicate the 
best modality correction. Due to the absence of definitive 
evidence, ESAs administration effects are unknown. The 
same guidelines focused attention on the importance of iron 
deficiency and its correction for quality of life and NYHA 
class improvement.67  However, among traditional therapies, 
the use of ESAs alone or together with iron represents the 
only potential option. Given the possible risks of worsen-
ing hypertension and thrombosis observed in the last study, 
the recent guidelines of American College of Physicians68 
conclude against the use of ESAs in patients with mild-to-
moderate anemia. On the other hand, IV iron administration 
appears to improve quality of life and exercise tolerance; for 
these reasons, it is accepted for reducing anemic status. Nev-
ertheless, we know from epidemiological data that iron defi-
ciency in HF, when defined as a serum ferritin below 100 g/L 
or a serum ferritin 100–299 g/L and transferrin ,20%, is 
found in about half of the CHF patients, so less than 50% of 
patients could potentially benefit from this treatment. Thus, an 
enormous question emerges from the epidemiological data: 
how can we treat the other residual patients? In our opinion, 
the “end” of ESA administration in anemic HF patients is 
long to be realized for several reasons: 1) we do not have 
other treatment options, particularly in patients without iron 
metabolism disorder; 2) most patients with anemic HF have a 
concomitant renal dysfunction, and the use of ESAs is com-
monly accepted in the nephrological setting, even if a recent 
trial showed negative results (Trial to Reduce cardiovascular 
Events with Aranesp Therapy [TREAT]);69 3) the starting 
Hb level in larger trials was 11.5 g/dL and is not a correct 
target to begin ESA treatment; in the same studies 30% of 
the population had atrial fibrillation and 70% had hyperten-
sion, both conditions that predispose to embolic events; 
4) the mean dosage of darbepoetin used was high, particu-
larly considering the baseline hematocrit values; 5) in dif-
ferent studies, ESAs were sometimes administered together 
with iron in different dosages and different modalities 
– some oral and some IV – and this represent a great bias; 
6) reports using low ESA dosage confirmed the more positive 
results. The latter point is in line with experimental studies 
in which low ESA administration was related to increased 
vascular and endothelial grow factors, increased expression 
of heavy chain of myoglobin as well as nitric oxide liberation. 
All these doubts and concerns deserve further investigations 
to address the optimal Hb intervention target, the clinical 
characteristic of patients, the comorbidities in which ESAs 
should be avoided, the etiology of anemia, and better clas-
sification of iron dysfunction. When the literature responds 
to all these points, we should obtain a definitive answer 
about the role of ESAs and their tailored dosage and rate of 
administration in HF with anemia. At present, we can assert 
that the use of high ESA dosage is potentially dangerous in 
subjects with a definite embolic risk. The use of the same 
agents at low dosage in patients with low embolic profile 
could still have a rationale.
Conclusion
The use of ESAs has recently demonstrated negative effects 
in anemic patients with HF. To prevent the negative effects, 
high dosage and chronic administration should be avoided. 
Nevertheless, few studies investigated the specific causes 
of anemia, providing different results regarding its etiology. 
Understanding the precise causes of anemia, acquiring 
greater knowledge of erythroid metabolism dysfunction, 
and elucidating the optimal Hb intervention target would 
facilitate more precise answers regarding the exact role of 
ESAs in this setting. 
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